HIGHLIGHTS
- who: Michael P. Flood from the DepartmentUniversity of, Melbourne, Australia have published the paper: ASO Author Reflections: Neoadjuvant Systemic Chemotherapy in Isolated Resectable Colorectal Peritoneal Metastases: Ready for Standard of Care?, in the Journal: (JOURNAL) of 25/03/2022
- what: Though the trial showed significant improvements in overall survival with surgery compared with chemotherapy alone less refined patient selection and a now outdated systemic chemotherapy regimen are thought to be responsible for (what would be considered today) the low median survival in the experimental arm (22.3 months).
SUMMARY
The challenging . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.